Clinical trials: Bone Marrow Transplantation
AML, ALL
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
Allogeneic stem cell transplantation may provide long-term remissions for some patients with hematological malignancies. However, allogeneic transplantation is associated with a significant risk of potentially life threatening…
- Conditions
- AML, ALL, CLL, Myelodysplastic Syndrome
- Trial name
- NCT00533923
- Testing
- Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Recurrent Severe Aplastic Anemia, Refractory Severe Aplastic Anemia
A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia
This phase I trial evaluates the safety and feasibility of using a reduced-intensity regimen of cyclophosphamide, pentostatin, and anti-thymocyte globulin prior to a CD4+ T-cell depleted haploidentical hematopoietic cell…
- Trial name
- NCT05757310
- Testing
- Anti-Thymocyte Globulin, Biospecimen Collection, Bone Marrow Aspirate
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
This phase II trial is for patients with acute lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome or chronic myeloid leukemia who have been referred for a peripheral blood stem cell transplantation to treat…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia
- Trial name
- NCT02220985
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Myelodysplastic Syndrome
GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant
This is a pilot study which will be done in a small number of patients. The purpose of this study is to test the safety and benefit of giving a type of chemotherapy - cyclophosphamide - after the transplant to prevent graft…
- Conditions
- Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT02360111
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Graft-Versus-Host Disease, Graft-versus-leukemia
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Bone marrow transplants (BMT) are one form of treatment for disorders of the blood, including leukemia. However, because the procedure is often associated with potentially life-threatening reactions, it is usually reserved for…
- Conditions
- Graft-Versus-Host Disease, Graft-versus-leukemia, Donor Apheresis
- Trial name
- NCT00001529
- Testing
- G-CSF
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Graft vs Host Disease, Hematologic Neoplasm
Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease
Blood contains different kinds of cells, white blood cells, red blood cells, and platelets. In order to treat certain diseases, specific cell types can be removed from blood and transplanted into patients.
- Trial name
- NCT00001872
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease
Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor bone marrow transplant helps stop the growth of abnormal cells.
- Trial name
- NCT00489281
- Testing
- Cyclophosphamide, Fludarabine, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Lymphoma
Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation
The National Marrow Donor Program (NMDP) has established a system for registering, matching, and tracking unrelated donor cord blood units (CBUs) and transplant outcomes.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00737516
- Testing
- HPC, Cord Blood
- Where
- 19 sites in United States
- Volunteers
- 3,621 people, healthy volunteers welcome
- Sponsor
- National Marrow Donor Program
Leukemia, Myelodysplastic Syndrome
Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
This study will test the safety of giving you specialized white cells from your donor. They are called WT1 sensitized T cells. They have been grown in the lab and are immunized against a protein.
- Trial name
- NCT00620633
- Testing
- WT1-sensitized T cells
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Reduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for…
- Conditions
- Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT05088356
- Testing
- Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Stanford University
Cardiovascular Complications, Leukemia
Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell Transplant
RATIONALE: Gathering information about how often metabolic syndrome occurs in young survivors of childhood leukemia who have undergone stem cell transplant may help doctors learn more about the disease and the long-term effects…
- Conditions
- Cardiovascular Complications, Leukemia, Long-term Effects Secondary to Cancer Therapy in Children, Metabolic Syndrome
- Trial name
- NCT00920842
- Where
- United States
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Immunocompromised
H1N1sw Vaccine in Adult Transplant Recipients
The trial investigates the efficacy of the adjuvanted H1N1 influenza vaccine Focetria(R) in immunocompromised adults who have undergone solid organ or bone marrow transplantation.
- Trial name
- NCT01069601
- Testing
- Focetria (2x H1N1 vaccine with MF59 adjuvants)
- Where
- Germany
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- HepNet Study House, German Liverfoundation
Knee Osteoarthritis
Laser Cell Therapy for Knee Cartilage Repair
Laser pulsed energy will be delivered over an optical fiber to create channels into damaged cartilage of the knee or knees. The channels have a diameter of approximately 100 microns or less and an approximate depth of 1…
- Trial name
- NCT04001361
- Testing
- Laser Cell Therapy
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Endocellutions
Sickle Cell Disease
SALT: Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease
We hope to gain valuable information about the safety, success of engraftment, and rates of complications using alternate donor transplantation for children with severe SCD.
- Trial name
- NCT00257543
- Testing
- Alternative donor bone marrow and cord blood
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Emory University
Disorder Related to Bone Marrow Transplantation, Blood Stem Cell Transplant Failure
Long Term Minor Sibling Donor Well-Being
The goal of this research study is to understand what it is like for a young person to have a sick family member and what it is like to donate bone marrow or stem cells for a sick family member. Primary Aims: 1.
- Conditions
- Disorder Related to Bone Marrow Transplantation, Blood Stem Cell Transplant Failure, Disturbance of Emotions Specific to Childhood and Adolescence, Transmission, Blood, Recipient/Donor
- Trial name
- NCT00667784
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Background: Allogeneic blood or marrow transplant is when stem cells are taken from one person s blood or bone marrow and given to another person. Researchers think this may help people with immune system problems.
- Conditions
- Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases, Autoimmune Lymphoproliferative
- Trial name
- NCT02579967
- Testing
- Immunosuppression Only Conditioning -Closed with amendment L, Reduced Intensity Conditioning, Myeloablative Conditioning-Closed with amendment L
- Where
- 2 sites in United States
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Blood And Marrow Transplantation
Plerixafor for Stem Cell Mobilization in Normal Donors
The goal of this clinical research study is to learn if treating stem cell donors with filgrastim (G-CSF) and plerixafor (Mozobil®) can cause them to produce a higher number of blood stem cells than filgrastim by itself.
- Trial name
- NCT01818284
- Testing
- Filgrastim, Plerixafor, Apheresis Procedure
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Complement Mediated Diseases
First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers
Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the complement inhibitor AMY-101.
- Trial name
- NCT03316521
- Testing
- AMY-101
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Amyndas Pharmaceuticals S.A.
Leukemia, Lymphoma
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Background: After an allogeneic hematopoietic stem cell transplant (HSCT), the donor genome is found in the recipient s circulation and tissues.
- Conditions
- Leukemia, Lymphoma, Hematologic Malignancy
- Trial name
- NCT06856226
- Testing
- Arm 1
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
GI Cancer, Lymphoma
Geriatric Communication Skills Training Program for Oncology Clinicians
The purpose of this study is to learn more about the effects of a training program designed to help doctors communicate better with older patients and their caregivers.
- Conditions
- GI Cancer, Lymphoma, GU Cancer, Bone Marrow Transplant
- Trial name
- NCT03530969
- Testing
- Self-Efficacy Assessment, UCLA Geriatrics Attitudes Scale, Course Evaluations
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center